If you’re one of the millions of Americans who have used compounded semaglutide for weight loss, the headlines in early 2026 were terrifying. “FDA Crackdown.” “DOJ Referral.” “Warning Letters to 30+ Companies.”
It felt like the rug was being pulled out from under you.
But here’s what the headlines didn’t tell you: compounding semaglutide is not banned. What the FDA targeted was the mass-marketing and mass-production of compounded GLP-1 products by companies treating them like generic drugs. Traditional, patient-specific compounding through licensed pharmacies for documented medical need remains a legal pathway.
This article breaks down exactly what changed, what didn’t, and what your options look like right now in 2026.
What the FDA Actually Announced on February 6, 2026
On February 6, 2026, FDA Commissioner Martin Makary issued a public statement announcing the agency’s intent to take “decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded products that are being mass-marketed directly to consumers.”
That last part is critical: mass-marketed directly to consumers.
The announcement came one day after Hims & Hers Health launched a compounded oral semaglutide product — marketed as containing “the same active ingredient as Wegovy” while acknowledging it was not FDA-approved. Within 48 hours, Hims pulled the product, and the HHS General Counsel referred the company to the Department of Justice for investigation.
The FDA’s enforcement statement was pointed: “Entities engaged in the manufacture, distribution, or marketing of unapproved compounded GLP-1 products should be aware that failure to adequately address any violations may result in legal action without further notice, including seizure and injunction.”
The Timeline That Led Here
This didn’t happen overnight. The FDA followed a clear enforcement escalation:
Key Dates
February 21, 2025: FDA resolved the national semaglutide shortage. The legal basis for broad compounding under shortage provisions began to end.
April 22, 2025: Enforcement discretion ended for 503A pharmacies (state-licensed, patient-specific compounding) making copies of FDA-approved semaglutide products.
May 22, 2025: Enforcement discretion ended for 503B outsourcing facilities compounding semaglutide.
September 2025 – ongoing: FDA began sending “thousands” of warning letters to telehealth companies and compounders about misleading advertising.
February 6, 2026: Commissioner Makary’s enforcement announcement.
March 2026: FDA sent warning letters to 30+ telehealth companies in a single batch, citing violations for comparing compounded products to FDA-approved drugs and claiming “generic” status.
What’s Actually Illegal Now
The FDA’s enforcement is targeting specific behaviors, not the concept of compounding itself. Here’s what crosses the line:
Mass-marketing compounded GLP-1s as alternatives to branded drugs. Companies cannot advertise compounded semaglutide as “the same active ingredient as Wegovy” or call it “generic semaglutide.” Under sections 502(a) and 502(bb) of the FD&C Act, those claims are considered false or misleading, making the products misbranded.
Mass-producing compounded GLP-1s without patient-specific prescriptions. Compounding was never intended for large-scale manufacturing. It exists to serve individual patients whose needs can’t be met by commercially available FDA-approved products.
Using unapproved salt forms. Some compounders have used semaglutide sodium or other salt forms rather than semaglutide base (the form used in FDA-approved products). The FDA considers these unapproved new drugs — not compounded versions of an existing drug.
Selling “research use only” peptides for human consumption. The FDA has warned companies selling semaglutide, tirzepatide, and even unapproved peptides like retatrutide labeled “for research purposes” or “not for human consumption” — with dosing instructions clearly intended for patient use.
What’s Still Legal
Despite the crackdown, the FDA has been clear that legitimate, patient-specific compounding remains a lawful pathway. Here’s what still works:
The Remaining Legal Pathway: Section 503A
Under Section 503A of the FD&C Act, a state-licensed pharmacy can compound a medication for an individual patient when:
1. There is a valid, patient-specific prescription from a licensed prescriber.
2. There is documented medical necessity — the patient’s need cannot be met by an FDA-approved product. Examples include a documented allergy to an inactive ingredient in Wegovy or Ozempic, or a medical need for a dosage form or strength not commercially available.
3. The pharmacy uses active pharmaceutical ingredients from FDA-registered sources.
4. The pharmacy is not essentially manufacturing the drug on a mass scale.
The key distinction the FDA drew in its clarification was important: the agency “did not signal a blanket prohibition on lawful, patient-specific compounding by state-licensed pharmacies.” Instead, it identified enforcement priorities: compounding without documented medical necessity, unlicensed manufacturing, misleading marketing, improper storage and shipping, and poor API sourcing.
What This Means for You as a Patient
If you’re currently using compounded semaglutide or tirzepatide, here’s your practical checklist:
1. Verify Your Pharmacy
Make sure your compounding pharmacy is state-licensed and operating under Section 503A. You can verify this through your state’s board of pharmacy website. Look for additional credentials like PCAB (Pharmacy Compounding Accreditation Board) accreditation or LegitScript certification.
2. Confirm Your Prescription Is Patient-Specific
Your prescription should come from a licensed prescriber who has evaluated your individual medical history. A 30-second online quiz followed by an automatic prescription does not meet the standard of a patient-specific evaluation. If your provider didn’t ask about your medical history, current medications, allergies, and health goals, that’s a red flag.
3. Ask About the API Source
The active pharmaceutical ingredient (semaglutide base) used in your compounded medication should come from an FDA-registered manufacturer. Ask your pharmacy directly. If they can’t answer or won’t tell you, consider that a warning sign.
4. Know Your Medical Justification
For compounding to be appropriate under the current rules, there needs to be a documented reason why an FDA-approved product doesn’t meet your needs. Cost alone is not sufficient medical justification under Section 503A. However, legitimate reasons include allergies to inactive ingredients, medical need for a specific dosage form, or the need for a concentration not available commercially.
5. Explore Your Expanding Options
The pricing landscape has shifted dramatically. The Wegovy pill (oral semaglutide) launched in January 2026 at $149 per month for the starting dose and $299 for the maintenance dose. Medicare will begin covering GLP-1s for weight loss in July 2026 at $50 per month. Employer coverage has expanded from 28% to 43% of large firms in a single year. The gap between compounded and branded pricing is shrinking fast.
The Bigger Picture: More Options Than Ever
Here’s the empowering reality that the panic headlines miss: even as the compounding pathway narrows, patient access to GLP-1 medications is expanding faster than ever.
The Wegovy pill offers a needle-free, no-refrigeration-needed option at a lower price point than compounded injectables from many providers. Eli Lilly’s orforglipron — another oral GLP-1 that doesn’t even require fasting before taking it — has an FDA target action date of April 10, 2026. Medicare coverage starts this summer. And branded prices continue to fall.
The compounding era served a critical purpose: it kept GLP-1 medications accessible to millions of people when branded versions were scarce and unaffordable. That era is evolving, not ending. The pathway is narrower, but the total landscape of affordable GLP-1 access is wider than it has ever been.
What We Don’t Know Yet
The regulatory landscape is still moving. Several lawsuits challenging FDA enforcement are working through the courts. The Outsourcing Facilities Association (OFA) case against the FDA saw a preliminary injunction denied in March 2025, but the underlying case continues. State-level rules vary and are evolving. We’ll update this article as new developments emerge.
The FDA has also indicated it may take further steps to restrict access to GLP-1 APIs for compounding, but specific regulations have not been finalized. The current enforcement posture relies on existing statutory authority, not new rules.
Your Next Step
Whether you continue with patient-specific compounding through a verified pharmacy or transition to a branded option like the Wegovy pill, the most important thing is that you have choices. The FDA crackdown was aimed at companies cutting corners — not at patients making informed decisions about their health.
If you’re ready to explore your current options, our provider comparison page shows you legitimate, licensed telehealth providers offering GLP-1 medications with proper medical evaluations, verified pharmacies, and transparent pricing.